Ticker: TRNS

07:46am, Wednesday, Mar 25, 2026

Merck Seals $6.7B Deal to Acquire Terns Pharmaceuticals and Boosts Oncology Pipeline

Merck is set to acquire Terns Pharmaceuticals for $6.7 billion, enhancing its oncology portfolio with TERN-701, a promising drug candidate targeting chronic myeloid leukemia.